NASDAQ:TBPH - Theravance Biopharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$26.26 -0.24 (-0.91 %)
(As of 07/16/2018 04:45 AM ET)
Previous Close$26.26
Today's Range$26.07 - $26.80
52-Week Range$21.27 - $40.66
Volume88,626 shs
Average Volume196,924 shs
Market Capitalization$1.44 billion
P/E RatioN/A
Dividend YieldN/A
Theravance Biopharma logoTheravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria. Its product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases. The company's product candidates also comprise Axelopran, an oral peripherally active mu opioid receptor antagonist that is in Phase II clinical trials for opioid induced constipation; Velusetrag (TD-5108), an oral and investigational medicine, which is in Phase II studies for gastrointestinal motility disorders; TD-8954, a selective 5-HT4 receptor agonist for gastrointestinal motility disorders; and TD-1473, a pan-Janus kinase inhibitor, which has completed phase I clinical studies for ulcerative colitis. In addition, it develops TD-0714, a Neprilysin inhibitor that has completed phase I clinical studies for heart failure and chronic kidney diseases; and TD-9855, an investigational norepinephrine and serotonin reuptake inhibitor, which is in Phase II clinical studies for neurogenic orthostatic hypotension. Further, the company focuses on various drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol for the treatment of COPD and asthma; the Inhaled Bifunctional Muscarinic Antagonist-Beta2 Agonist program, as monotherapy; and in combination with other therapeutically active components, such as an inhaled corticosteroid. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.

Receive TBPH News and Ratings via Email

Sign-up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity Ratio3.53
Current Ratio4.25
Quick Ratio4.08


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$15.39 million
Price / Sales93.59
Cash FlowN/A
Price / CashN/A
Book Value$2.13 per share
Price / Book12.33


EPS (Most Recent Fiscal Year)($5.45)
Net Income$-285,400,000.00
Net Margins-1,383.47%
Return on Equity-188.96%
Return on Assets-58.47%


Outstanding Shares54,850,000
Market Cap$1,440.47

The Truth About Cryptocurrencies

Theravance Biopharma (NASDAQ:TBPH) Frequently Asked Questions

What is Theravance Biopharma's stock symbol?

Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."

How were Theravance Biopharma's earnings last quarter?

Theravance Biopharma Inc (NASDAQ:TBPH) issued its quarterly earnings data on Tuesday, May, 8th. The biopharmaceutical company reported ($1.22) earnings per share for the quarter, beating analysts' consensus estimates of ($1.26) by $0.04. The biopharmaceutical company had revenue of $8.32 million for the quarter, compared to analysts' expectations of $5.74 million. Theravance Biopharma had a negative net margin of 1,383.47% and a negative return on equity of 188.96%. View Theravance Biopharma's Earnings History.

What price target have analysts set for TBPH?

6 brokerages have issued 1-year target prices for Theravance Biopharma's shares. Their forecasts range from $22.00 to $55.00. On average, they anticipate Theravance Biopharma's stock price to reach $39.6667 in the next twelve months. This suggests a possible upside of 51.1% from the stock's current price. View Analyst Ratings for Theravance Biopharma.

What is the consensus analysts' recommendation for Theravance Biopharma?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theravance Biopharma in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Theravance Biopharma stock?

Here are some recent quotes from research analysts about Theravance Biopharma stock:
  • 1. Needham & Company LLC analysts commented, "Theravance provided a quarterly corporate update yesterday. Mgmt guided for TD-9855 data in Neurogenic Orthostatic Hypotension (NOH) in Jul 2018 (was 2Q18). Impact on symptoms (dizziness) through 4wks will be key. There are limitations to the trial, however, including a small number of patients and no placebo arm. Nevertheless, mgmt is optimistic for Phase 3 initiation by YE18. FDA reportedly requiring a large safety trial for velusetrag, prompting Theravance to stop development in the U.S. Collaborator Alfasigma consequently exercised its option for WW rights and will pursue development in EU. TD-1473 trial initiations in Disease are still on track for 2H18. Reiterate BUY, but reducing price target to $40 (was $45) to reflect decision not to develop velusetrag in U.S." (5/9/2018)
  • 2. According to Zacks Investment Research, "Theravance has a single marketed product in its portfolio called Vibativ. Moreover, its pipeline programs are targeting highly competitive therapeutic areas. Also, any agreement termination might be a huge setback for the company as in the past. Shares of the company have underperformed the industry in a year’s time. However, we are upbeat about Theravance’s efforts to expand Vibativ’s label, which if approved for additional indications, would be commercially significant. Moreover, the company’s regulatory filing for revefenacin for treating chronic obstructive pulmonary disease was accepted by the FDA in January 2018 with a response expected by this year-end. Estimates have been going down lately ahead of the company’s Q1 earnings release. The company has negative record of earnings surprises in recent quarters." (5/1/2018)
  • 3. Cantor Fitzgerald analysts commented, "Positives from the quarter: 1) An sNDA was filed for the use of Trelegy Ellipta for an expanded indication for the maintenance treatment of airflow obstruction and reduction of exacerbations in patients with COPD. TBPH is entitled to receive an 85% economic interest in the royalties paid by GSK (Not Covered) on worldwide net sales; 2) Trelegy Ellipta was granted marketing authorization in Europe for the treatment of COPD; 3) in November, TBPH and MYL (Neutral) announced the submission of an NDA for revefenacin (TD-4208) in adults with COPD; 4) at the 2017 Annual CHEST Meeting, TBPH and MYL announced the presentation of additional positive efficacy data from the three- month, pivotal Phase 3 studies of revefenacin (TD-4208); 5) progression of inhaled JAK inhibitor into first-in-human studies in late-2018/early-2019; 6) TBPH expects to provide an update in 1H18 regarding its dialogue with U.S. and EU regulators on Phase 3 requirements for the velusetrag/TD-5108 program in gastroparesis; 7) cash and equivalents totaled ~$390MM at 12/31/17. This excludes the $100MM upfront payment received in February 2018, from the announced collaboration with Janssen (Not Covered)." (2/27/2018)

Who are some of Theravance Biopharma's key competitors?

Who are Theravance Biopharma's key executives?

Theravance Biopharma's management team includes the folowing people:
  • Mr. Rick E. Winningham, Chairman & CEO (Age 58)
  • Ms. Renée D. Galá, Sr. VP, CFO & Treasurer (Age 46)
  • Mr. Bradford J. Shafer, Exec. VP, Gen. Counsel & Sec. (Age 58)
  • Dr. Sharathchandra S. Hegde, Sr. VP of Research (Age 54)
  • Dr. Phillip D. Worboys, Sr. VP of Translational Science (Age 48)

Has Theravance Biopharma been receiving favorable news coverage?

News articles about TBPH stock have trended positive this week, according to Accern Sentiment. Accern identifies positive and negative press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Theravance Biopharma earned a daily sentiment score of 0.36 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 45.05 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of Theravance Biopharma?

Shares of TBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Theravance Biopharma's stock price today?

One share of TBPH stock can currently be purchased for approximately $26.26.

How big of a company is Theravance Biopharma?

Theravance Biopharma has a market capitalization of $1.44 billion and generates $15.39 million in revenue each year. The biopharmaceutical company earns $-285,400,000.00 in net income (profit) each year or ($5.45) on an earnings per share basis. Theravance Biopharma employs 340 workers across the globe.

How can I contact Theravance Biopharma?

Theravance Biopharma's mailing address is UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104. The biopharmaceutical company can be reached via phone at 650-808-6000 or via email at [email protected]

MarketBeat Community Rating for Theravance Biopharma (NASDAQ TBPH)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  166 (Vote Outperform)
Underperform Votes:  203 (Vote Underperform)
Total Votes:  369
MarketBeat's community ratings are surveys of what our community members think about Theravance Biopharma and other stocks. Vote "Outperform" if you believe TBPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TBPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.